Presented at ASCO 2016 the outcomes of the OxOnc Study in which the test has properly supported the completion of a Phase 2 study of crizotinib in patients with ROS1-Positive Non-Small Cell Lung Cancer
The OxOnc Study met its primary objective of demonstrating a high overall response rate for crizotinib. It enrolled 127 ROS1-positive patients in the People’s Republic of China (PRC), Japan, Taiwan and South Korea by using AmoyDx® ROS1 gene fusions test, and is the largest ROS1-positive NSCLC cohort reported to date. Results from the OxOnc Study were presented at the recent 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
For more information